Trialstirzepatidemayo clinicgerdclinicaltrials.gov

Mayo Clinic registers Phase 4 tirzepatide reflux and gastric physiology study

The crossover-style comparison against saline placebo uses 96-hour wireless pH recording starting about 48 hours after dosing.

By Priya Raman · Science Reporter

Oct 26 08:00 ETSource: ClinicalTrials.gov

The wire

01ClinicalTrials.gov entry NCT07893457 will test whether a single 7.5 mg subcutaneous dose of tirzepatide increases total esophageal acid exposure time versus saline placebo in adults with obesity.
02Reflux and delayed gastric emptying are recurring clinical questions for incretin prescribers, and this study targets esophagogastric junction mechanics directly rather than relying on symptom reports.
03The trial is listed as not yet recruiting with a start date of October 26, 2026, and it examines a single acute dose, not chronic therapy.

From the source

Effects of Tirzepatide on Esophagogastric Junction Mechanics, Reflux Burden, and Gastric Physiology in Adults With Obesity
NCT07893457 · PHASE4 · NOT YET RECRUITING · Sponsor: Mayo Clinic · Conditions: Obese Adults.

Read at clinicaltrials.gov

Source URL https://clinicaltrials.gov/study/NCT07893457